CDXS Stock Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Codexis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.61 |
| 52 Week High | US$4.91 |
| 52 Week Low | US$1.85 |
| Beta | 2.07 |
| 11 Month Change | 50.65% |
| 3 Month Change | 51.15% |
| 1 Year Change | 127.09% |
| 33 Year Change | -87.41% |
| 5 Year Change | -70.33% |
| Change since IPO | -65.23% |
Recent News & Updates
Recent updates
Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors
Nov 07
After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar
Jul 26Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Jul 12Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects
May 29Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Shareholder Returns
| CDXS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 18.8% | -2.3% | 0.3% |
| 1Y | 127.1% | 3.1% | 31.1% |
Return vs Industry: CDXS exceeded the US Life Sciences industry which returned 3.1% over the past year.
Return vs Market: CDXS exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| CDXS volatility | |
|---|---|
| CDXS Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CDXS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CDXS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 174 | Stephen Dilly | www.codexis.com |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
Codexis, Inc. Fundamentals Summary
| CDXS fundamental statistics | |
|---|---|
| Market cap | US$352.37m |
| Earnings (TTM) | -US$62.09m |
| Revenue (TTM) | US$64.45m |
5.8x
P/S Ratio-6.0x
P/E RatioIs CDXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXS income statement (TTM) | |
|---|---|
| Revenue | US$64.45m |
| Cost of Revenue | US$60.89m |
| Gross Profit | US$3.55m |
| Other Expenses | US$65.64m |
| Earnings | -US$62.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 5.51% |
| Net Profit Margin | -96.35% |
| Debt/Equity Ratio | 39.0% |
How did CDXS perform over the long term?
See historical performance and comparison